EYLEA® (Non-English)

EYLEA Key Features and Benefits

EYLEA® (aflibercept), just like Eylea HD, offers anti-VEGF treatment to improve eye health. They inhibit VEGF, reducing abnormal blood vessel growth and fluid leakage to effectively treat various vision-threatening retinal diseases.

• Mechanism of Action: Blocks VEGF-A and Placental Growth Factor (PlGF) to prevent abnormal blood vessel formation.
• Proven Efficacy: Reduces retinal swelling and prevents vision loss.
• Longer Dosing Intervals: Extended treatment intervals up to 16 weeks.
• Multiple Indications: Approved for wet AMD, diabetic macular edema, and retinal vein occlusion.

EYLEA Indications

EYLEA® is one of the popular drugs indicated for patients with vision impairment due to retinal conditions caused by excessive VEGF activity. Baseline measurements of visual acuity and retinal thickness are taken before starting EYLEA® treatment to evaluate its effectiveness over time.

• Neovascular (Wet) Age-Related Macular Degeneration (AMD): Reduces vision loss by decreasing abnormal blood vessel growth.
• Diabetic Macular Edema (DME): Controls macular swelling in diabetes-related retinal damage.
• Retinal Vein Occlusion (RVO): Treats macular edema from branch (BRVO) or central (CRVO) retinal vein occlusion.
• Myopic Choroidal Neovascularization (mCNV): Prevents further vision loss due to excessive neovascularization in severe myopia.

EYLEA (Aflibercept) Ingredients

EYLEA (aflibercept) ingredients ensures VEGF are blocked effectively, helping to control retinal conditions. Each single-dose vial or pre-filled syringe contains aflibercept, setting it apart from biosimilar alternatives.

• Active Ingredient: Aflibercept 40 mg/mL.
• Excipients:
  • Polysorbate 20
  • Sodium phosphate monohydrate
  • Sucrose
  • Water for injection

How is EYLEA Administered

EYLEA administered as an intravitreal injection by a trained ophthalmologist to treat conditions like macular oedema. The dosing schedule and information for Eylea patient injection varies depending on the indication.

Standard Dosing Regimen

• Wet AMD: 2 mg (0.05 mL) every 4 weeks for the first 3 months, followed by every 8-16 weeks.
• DME: 2 mg every 4 weeks for the first 5 injections, then every 8 weeks.
• RVO (BRVO or CRVO): 2 mg every 4 weeks until stabilization.
• mCNV: Single 2 mg injection, with additional doses if needed.

Possible Side Effects on EYLEA Patients

The most commonly reported and shared reviews on Eylea side effects include temporary eye discomfort, increased intraocular pressure, and mild inflammation. However, serious complications can occur.

• Common Side Effects (≥1%):
  • Eye pain, redness, blurred vision
  • Floaters, increased eye pressure, mild inflammation
  • Mild bleeding at the injection site
• Serious Risks:
  • Endophthalmitis: Severe eye infection requiring urgent treatment.
  • Retinal Detachment: May cause sudden vision loss.
  • Increased Risk of Stroke: Reported in some Eylea patients treated with vascular diseases.
  • Intraocular Inflammation: May require anti-inflammatory treatment.

Clinical Studies on EYLEA Patients

Clinical studies on EYLEA® patients have confirmed the FDA-approved treatment’s effectiveness in improving vision and reducing retinal edema across multiple conditions. The label includes detailed information about the benefits of Eylea treatment, including improved visual acuity and reduced swelling.

Wet AMD Trials

• VIEW 1 & VIEW 2 Studies:
  • 96% of patients maintained vision after 1 year.
  • 70% experienced improved visual acuity.
  • Similar effectiveness to ranibizumab, but with fewer injections.

Diabetic Macular Edema (DME) Trials

• VISTA & VIVID Studies:
  • EYLEA® improved vision by +10 letters on average.
  • 52% of patients had significant visual improvement.
  • Sustained results over 2 years with less frequent dosing.

Retinal Vein Occlusion (RVO) Trials

• COPERNICUS & GALILEO Trials (CRVO):
  • 56% of patients gained 15 or more letters in vision.
  • Significant retinal fluid reduction within 6 months.
• VIBRANT Trial (BRVO):
  • EYLEA® demonstrated superior improvement compared to laser therapy.

EYLEA® Manufacturer Information

Eylea, approved by the European Medicines Agency in 2012, treats various eye conditions using aflibercept.

• Manufacturer: Regeneron Pharmaceuticals, Inc.
• Co-Marketed by: Bayer AG
• Customer Support: Contact local distributor or prescribing physician.
• Adverse Event Reporting: Report to local regulatory agencies or EYLEA® manufacturer.

EYLEA FAQ

1. How long does it take for EYLEA® to work?

• Some patients notice improvements within 1 week, while full benefits may take several months.

2. Can EYLEA® be self-administered?

• No, EYLEA® must be administered by an ophthalmologist in a sterile clinical setting.

3. What happens if I miss an injection?

• Contact your doctor immediately to reschedule and prevent disease progression.

4. Can I receive other eye treatments while on EYLEA®?

• Yes, but consult your doctor to avoid interactions with steroids or other injections.

5. Is EYLEA® safe for pregnant or breastfeeding women?

• There is limited data on use during pregnancy or lactation. Use only if benefits outweigh risks.

6. What should I do after receiving an injection?

• Avoid rubbing the eye, swimming, or heavy lifting for at least 3 days.
• Monitor for infection symptoms (pain, redness, vision loss) and report immediately.